{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:09:25Z","timestamp":1788858565384,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01826-y","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:31:15Z","timestamp":1788856275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating Antibody\u2013Drug Conjugate Sequencing in Gastric Cancer: Cross-Resistance Biology, Target Switching, and Decision-Making Frameworks for the Post-Progression Landscape"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3200-6263","authenticated-orcid":false,"given":"Yue","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"3","key":"1826_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"1826_CR2","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","volume":"14","author":"JA Ajani","year":"2016","unstructured":"Ajani JA, D\u2019Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(10):1286\u2013312.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7517","key":"1826_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"9742","key":"1826_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"7","key":"1826_CR5","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","volume":"30","author":"K Shitara","year":"2024","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933\u201342. https:\/\/doi.org\/10.1038\/s41591-024-02992-x.","journal-title":"Nat Med"},{"issue":"25","key":"1826_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Iwasa S, Takashima T, et al. Trastuzumab deruxtecan in previously treated HER2-positive advanced gastric or gastroesophageal junction cancer (DESTINY-Gastric01): a randomized, multicenter, open-label, phase 2 trial. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"1826_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, et al. Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer. N Engl J Med. 2025;393(4):336\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2503119.","journal-title":"N Engl J Med"},{"key":"1826_CR8","volume-title":"Clinical guidelines for the diagnosis and treatment of gastric cancer (2026 edition, in Chinese)","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2026","unstructured":"Chinese Society of Clinical Oncology (CSCO). Clinical guidelines for the diagnosis and treatment of gastric cancer (2026 edition, in Chinese). Beijing: People\u2019s Medical Publishing House; 2026."},{"issue":"16","key":"1826_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED. Disitamab vedotin: first approval. Drugs. 2021;81(16):1929\u201335. https:\/\/doi.org\/10.1007\/s40265-021-01614-x.","journal-title":"Drugs"},{"key":"1826_CR10","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1b\/2 trial. EClinicalMedicine. 2024;68:102415. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102415.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"1826_CR11","first-page":"2736","volume":"123","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target whose expression is restricted to tumors. Int J Cancer. 2008;123(12):2736\u201343.","journal-title":"Int J Cancer"},{"issue":"10389","key":"1826_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): primary analysis of a phase 3, randomised, placebo-controlled trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet"},{"issue":"8","key":"1826_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02465-7.","journal-title":"Nat Med"},{"issue":"9","key":"1826_CR14","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","volume":"31","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Wu HX, Luo SX, et al. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nat Med. 2025;31(9):3037\u201346. https:\/\/doi.org\/10.1038\/s41591-025-03781-w.","journal-title":"Nat Med"},{"issue":"9","key":"1826_CR15","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang J, Sun Y, et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31(9):3028\u201336. https:\/\/doi.org\/10.1038\/s41591-025-03783-8.","journal-title":"Nat Med"},{"issue":"2","key":"1826_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Liu FR, Wei XL, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2025;26(2):227\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(24)00636-3.","journal-title":"Lancet Oncol"},{"issue":"7Supplement","key":"1826_CR17","doi-asserted-by":"publisher","first-page":"CT038","DOI":"10.1158\/1538-7445.AM2024-CT038","volume":"84","author":"J Rodon","year":"2024","unstructured":"Rodon J, Wainberg ZA, Zhang M, et al. Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a phase 2 study (Abstract CT038). Cancer Res. 2024;84(7Supplement):CT038. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT038.","journal-title":"Cancer Res"},{"issue":"1","key":"1826_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Baik C, Su WC, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12(1):74\u201389. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0715.","journal-title":"Cancer Discov"},{"issue":"29","key":"1826_CR19","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","volume":"35","author":"E Dotan","year":"2017","unstructured":"Dotan E, Cohen SJ, Starodub AN, et al. Phase I\/II trial of labetuzumab govitecan (anti-CEACAM5\/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017;35(29):3338\u201346.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1826_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s10120-025-01703-w","volume":"29","author":"W Li","year":"2026","unstructured":"Li W, Cheng M, Han H, et al. Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms. Gastric Cancer. 2026;29(2):300\u201320. https:\/\/doi.org\/10.1007\/s10120-025-01703-w.","journal-title":"Gastric Cancer"},{"issue":"7","key":"1826_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039\u201346.","journal-title":"Cancer Sci"},{"issue":"7","key":"1826_CR22","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(23)00215-2.","journal-title":"Lancet Oncol"},{"key":"1826_CR23","doi-asserted-by":"publisher","first-page":"103404","DOI":"10.1016\/j.eclinm.2025.103404","volume":"87","author":"Z Peng","year":"2025","unstructured":"Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced\/metastatic gastric or gastroesophageal junction cancer (DESTINY-Gastric06). EClinicalMedicine. 2025;87:103404. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103404.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1826_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F, Liu Y, Zhou X, et al. Disitamab vedotin: a novel antibody-drug conjugate for cancer therapy. Drug Deliv. 2022;29(1):1335\u201344. https:\/\/doi.org\/10.1080\/10717544.2022.2069883.","journal-title":"Drug Deliv"},{"issue":"7","key":"1826_CR25","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-22-0456","volume":"28","author":"J Zhang","year":"2022","unstructured":"Zhang J, Ji D, Shen W, et al. Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer. Clin Cancer Res. 2022;28(7):1292\u2013301. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0456.","journal-title":"Clin Cancer Res"},{"key":"1826_CR26","unstructured":"ClinicalTrials.gov. A first-in-human study of multiple doses of BB-1701 in subjects with locally advanced\/metastatic HER2 expressing solid tumors. NCT04257110. https:\/\/clinicaltrials.gov\/study\/NCT04257110. Accessed 12 Aug 2026."},{"issue":"1","key":"1826_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","volume":"18","author":"Q Ouyang","year":"2025","unstructured":"Ouyang Q, Rodon J, Liang Y, et al. Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. 2025;18(1):61. https:\/\/doi.org\/10.1186\/s13045-025-01705-2.","journal-title":"J Hematol Oncol"},{"issue":"35","key":"1826_CR28","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41(35):5363\u201375. https:\/\/doi.org\/10.1200\/JCO.23.01476.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1826_CR29","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1038\/s41591-025-03843-z","volume":"31","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Boni V, Kato K, et al. Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med. 2025;31(10):3504\u201313. https:\/\/doi.org\/10.1038\/s41591-025-03843-z.","journal-title":"Nat Med"},{"issue":"24","key":"1826_CR30","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","volume":"26","author":"S Decary","year":"2020","unstructured":"Decary S, Berne PF, Nicolazzi C, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res. 2020;26(24):6589\u201399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-4051.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1826_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10637-017-0439-y","volume":"35","author":"K Almhanna","year":"2017","unstructured":"Almhanna K, Miron ML, Wright D, et al. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing or not expressing guanylyl cyclase C. Invest New Drugs. 2017;35(2):235\u201341. https:\/\/doi.org\/10.1007\/s10637-017-0439-y.","journal-title":"Invest New Drugs"},{"key":"1826_CR32","unstructured":"ClinicalTrials.gov. A study of TAK-164 in participants with advanced gastrointestinal (GI) cancer expressing guanylyl cyclase C (GCC). NCT03449030. https:\/\/clinicaltrials.gov\/study\/NCT03449030. Accessed 12 Aug 2026."},{"issue":"4","key":"1826_CR33","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/cas.70319","volume":"117","author":"Y Murase","year":"2026","unstructured":"Murase Y, Nanjo S, Arai S, et al. Therapeutic strategies to overcome payload resistance of trastuzumab deruxtecan in HER2-positive cancers. Cancer Sci. 2026;117(4):996\u20131009. https:\/\/doi.org\/10.1111\/cas.70319.","journal-title":"Cancer Sci"},{"issue":"3","key":"1826_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac063","volume":"1","author":"R Tomabechi","year":"2022","unstructured":"Tomabechi R, Kishimoto H, Sato T, et al. SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1. PNAS Nexus. 2022;1(3):pgac063. https:\/\/doi.org\/10.1093\/pnasnexus\/pgac063.","journal-title":"PNAS Nexus"},{"issue":"24","key":"1826_CR35","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","volume":"24","author":"K Kinneer","year":"2018","unstructured":"Kinneer K, Meekin J, Tiberghien AC, et al. SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads. Clin Cancer Res. 2018;24(24):6570\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1300.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1826_CR36","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, et al. Cleavable linkers in antibody-drug conjugates. Chem Soc Rev. 2019;48(16):4361\u201374. https:\/\/doi.org\/10.1039\/c8cs00676h.","journal-title":"Chem Soc Rev"},{"issue":"20","key":"1826_CR37","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1826_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0.","journal-title":"Protein Cell"},{"issue":"2","key":"1826_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3978\/j.issn.1000-9604.2014.12.09","volume":"27","author":"Z Peng","year":"2015","unstructured":"Peng Z, Zou J, Zhang X, et al. HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chin J Cancer Res. 2015;27(2):163\u201371. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2014.12.09.","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"1826_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","volume":"10","author":"C Valenza","year":"2024","unstructured":"Valenza C, Guidi L, Battaiotto E, et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer. 2024;10(2):113\u201323. https:\/\/doi.org\/10.1016\/j.trecan.2023.11.001.","journal-title":"Trends Cancer"},{"key":"1826_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.09.024","volume":"105","author":"H Saeki","year":"2018","unstructured":"Saeki H, Oki E, Kashiwada T, et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). Eur J Cancer. 2018;105:41\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.024.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1826_CR42","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","volume":"68","author":"DS Wang","year":"2019","unstructured":"Wang DS, Liu ZX, Lu YX, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019;68(7):1152\u201361. https:\/\/doi.org\/10.1136\/gutjnl-2018-316522.","journal-title":"Gut"},{"issue":"3","key":"1826_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241\u201350.","journal-title":"N Engl J Med"},{"issue":"6","key":"1826_CR44","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/ijc.10410","volume":"99","author":"SA Price-Schiavi","year":"2002","unstructured":"Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99(6):783\u201391. https:\/\/doi.org\/10.1002\/ijc.10410.","journal-title":"Int J Cancer"},{"issue":"12","key":"1826_CR45","first-page":"4744","volume":"61","author":"MA Molina","year":"2001","unstructured":"Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61(12):4744\u20139.","journal-title":"Cancer Res"},{"issue":"12","key":"1826_CR46","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15(12):2825\u201334. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0408.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1826_CR47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon RP, Bovee TD, Doronina SO, et al. Reducing hydrophobicity of antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33(7):733\u20135. https:\/\/doi.org\/10.1038\/nbt.3212.","journal-title":"Nat Biotechnol"},{"key":"1826_CR48","first-page":"123","volume":"79","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Eur J Cancer. 2017;79:123\u201333.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1826_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1826_CR50","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1826_CR51","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"6230","key":"1826_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.","journal-title":"Science"},{"issue":"3","key":"1826_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31(3):311\u201325.","journal-title":"Cancer Cell"},{"issue":"3","key":"1826_CR54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399\u2013408.","journal-title":"Cell"},{"issue":"5","key":"1826_CR55","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"1826_CR56","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.04.005","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10(7):627\u201342. https:\/\/doi.org\/10.1016\/j.trecan.2024.04.005.","journal-title":"Trends Cancer"},{"issue":"2","key":"1826_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae238","volume":"30","author":"Y Kwak","year":"2025","unstructured":"Kwak Y, Kim TY, Nam SK, et al. Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression. Oncologist. 2025;30(2):oyae238. https:\/\/doi.org\/10.1093\/oncolo\/oyae238.","journal-title":"Oncologist"},{"issue":"12","key":"1826_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104000","volume":"9","author":"TY Kim","year":"2024","unstructured":"Kim TY, Kwak Y, Nam SK, et al. Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. ESMO Open. 2024;9(12):104000. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104000.","journal-title":"ESMO Open"},{"issue":"3","key":"1826_CR59","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/cancers17030340","volume":"17","author":"M Korpan","year":"2025","unstructured":"Korpan M, Puhr HC, Berger JM, et al. Current landscape of molecular biomarkers in gastroesophageal tumors and potential strategies for co-expression patterns. Cancers (Basel). 2025;17(3):340. https:\/\/doi.org\/10.3390\/cancers17030340.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1826_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449\u201356.","journal-title":"Nat Med"},{"issue":"1","key":"1826_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1826_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","volume":"8","author":"E Pectasides","year":"2018","unstructured":"Pectasides E, Stachler MD, Derks S, et al. Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma. Cancer Discov. 2018;8(1):37\u201348. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0395.","journal-title":"Cancer Discov"},{"issue":"7","key":"1826_CR63","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41576-019-0114-6","volume":"20","author":"S Turajlic","year":"2019","unstructured":"Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer. Nat Rev Genet. 2019;20(7):404\u201316.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"1826_CR64","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell. 2020;37(4):471\u201384.","journal-title":"Cancer Cell"},{"issue":"8","key":"1826_CR65","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","volume":"18","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Kawazoe A, Lordick F, et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18(8):473\u201387. https:\/\/doi.org\/10.1038\/s41571-021-00492-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1826_CR66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","volume":"8","author":"YY Janjigian","year":"2018","unstructured":"Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8(1):49\u201358. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0787.","journal-title":"Cancer Discov"},{"issue":"1","key":"1826_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbaf038","volume":"9","author":"B Zhang","year":"2026","unstructured":"Zhang B, Zhang L, Liu C, et al. Identification of factors conferring resistance to trastuzumab deruxtecan in advanced gastric cancer: a translational study from the single-arm, phase II, DESTINY-Gastric06 trial. Precis Clin Med. 2026;9(1):pbaf038. https:\/\/doi.org\/10.1093\/pcmedi\/pbaf038.","journal-title":"Precis Clin Med"},{"issue":"1","key":"1826_CR68","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.1038\/s41467-024-51271-3","volume":"15","author":"H Singh","year":"2024","unstructured":"Singh H, Lowder KE, Kapner K, et al. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2\u2009+\u2009gastroesophageal adenocarcinoma. Nat Commun. 2024;15(1):6833. https:\/\/doi.org\/10.1038\/s41467-024-51271-3.","journal-title":"Nat Commun"},{"issue":"23","key":"1826_CR69","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1158\/1078-0432.CCR-19-1704","volume":"25","author":"SB Maron","year":"2019","unstructured":"Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res. 2019;25(23):7098\u2013112. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1704.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1826_CR70","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s44321-026-00399-4","volume":"18","author":"Z Zhou","year":"2026","unstructured":"Zhou Z, Cutts R, Hrebien S, et al. ctDNA monitoring using tumor-informed copy number analysis. EMBO Mol Med. 2026;18(4):1429\u201355. https:\/\/doi.org\/10.1038\/s44321-026-00399-4.","journal-title":"EMBO Mol Med"},{"issue":"224","key":"1826_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094.","journal-title":"Sci Transl Med"},{"issue":"16","key":"1826_CR72","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36(16):1631\u201341. https:\/\/doi.org\/10.1200\/JCO.2017.76.8671.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1826_CR73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11523-017-0493-6","volume":"12","author":"Y Mishima","year":"2017","unstructured":"Mishima Y, Matsusaka S, Chin K, et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients. Target Oncol. 2017;12(3):341\u201351. https:\/\/doi.org\/10.1007\/s11523-017-0493-6.","journal-title":"Target Oncol"},{"issue":"4","key":"1826_CR74","doi-asserted-by":"publisher","first-page":"394","DOI":"10.5009\/gnl18484","volume":"13","author":"MW Lee","year":"2019","unstructured":"Lee MW, Kim GH, Jeon HK, et al. Clinical application of circulating tumor cells in gastric cancer. Gut Liver. 2019;13(4):394\u2013401. https:\/\/doi.org\/10.5009\/gnl18484.","journal-title":"Gut Liver"},{"issue":"6294","key":"1826_CR75","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aaf2403","volume":"353","author":"PL St\u00e5hl","year":"2016","unstructured":"St\u00e5hl PL, Salm\u00e9n F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78\u201382.","journal-title":"Science"},{"issue":"7871","key":"1826_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-021-03634-9","volume":"596","author":"A Rao","year":"2021","unstructured":"Rao A, Barkley D, Fran\u00e7a GS, et al. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596(7871):211\u201320. https:\/\/doi.org\/10.1038\/s41586-021-03634-9.","journal-title":"Nature"},{"key":"1826_CR77","volume-title":"National Reimbursement Drug List (NRDL) 2025 edition","author":"National Healthcare Security Administration","year":"2025","unstructured":"National Healthcare Security Administration. National Reimbursement Drug List (NRDL) 2025 edition. Beijing: NHSA; 2025."},{"key":"1826_CR78","unstructured":"National Medical Products Administration. Approval of trastuzumab deruxtecan for HER2-positive gastric cancer. NMPA announcement, January 22, 2026."},{"issue":"1","key":"1826_CR79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10120-024-01555-w","volume":"28","author":"H Kawakami","year":"2025","unstructured":"Kawakami H, Nakanishi K, Makiyama A, et al. Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study). Gastric Cancer. 2025;28(1):51\u201361. https:\/\/doi.org\/10.1007\/s10120-024-01555-w.","journal-title":"Gastric Cancer"},{"key":"1826_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1807824","volume":"16","author":"P Cheng","year":"2026","unstructured":"Cheng P, Ge J, Huang S, et al. Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world. Front Oncol. 2026;16:1807824. https:\/\/doi.org\/10.3389\/fonc.2026.1807824.","journal-title":"Front Oncol"},{"key":"1826_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-026-01465-3","author":"S Anaganti","year":"2026","unstructured":"Anaganti S, et al. Development of a translational murine model for ADC-induced interstitial lung disease. npj Precis Oncol. 2026. https:\/\/doi.org\/10.1038\/s41698-026-01465-3.","journal-title":"npj Precis Oncol"},{"issue":"22","key":"1826_CR82","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407086.","journal-title":"N Engl J Med"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01826-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01826-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:31:19Z","timestamp":1788856279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01826-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01826-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"91"}}